Keytruda®

Understanding Keytruda® 

Keytruda® (pembrolizumab) is a monoclonal antibody that targets PD-1 (programmed death-1), a protein on T cellsthat normally helps regulate immune responses. By blocking PD-1, Keytruda® enhances the immune system’s ability to recognize and attack cancer cells. It is widely used to treat various cancers, including those of the lung, skin, head & neck, bladder, and gastrointestinal tract.

How Keytruda® Works:

• Inhibits PD-1, preventing cancer cells from evading immune detection.
• Activates the immune system, helping it recognize and destroy tumors.
• Used across multiple cancer types, either alone or in combination with other treatments.

FDA Approval:

• Keytruda® (pembrolizumab): First approved on September 4, 2014, for advanced melanoma, with expanded approvals for multiple cancer types over the years.

For more information, please visit the Keytruda® patient website and speak with your healthcare provider to determine if Keytruda® is the right treatment option for you.